

9 July 2019

THC Global Agreement Update

- **THC Global (ASX:THC) has announced that it has been granted a medicinal cannabis manufacturing licence at its facility in Southport giving it the licensing required for the commercial production of medicinal cannabis products and undertaking a larger R&D program.**
- **EVE Investments, via its agreement with THC Global, now has access to the largest bio-pharmaceutical extraction facility in the Southern Hemisphere for R&D with THC Global of the Company's cannabis honey products.**
- **THC Global is currently producing a variety of Melaleuca Tea Tree extracts at its Southport facility on behalf of Eve Investments.**

EVE Investments Limited ("EVE") (ASX:EVE) provides the market with an update on its agreements with THC Global Group Limited (THC Global) (ASX:THC). The agreements encompass site lease, tea-tree off-take, cannabis off-take, and are directed towards the organic farming operations of THC Global as well as the development of novel tea-tree and cannabis products by both THC Global and EVE.

Medicinal Cannabis Honey

EVE, via its 100% subsidiaries Jenbrook and Meluka Honey, has an agreement with THC Global for the planned growth of cannabis at the site of its tea tree plantation. Under this agreement EVE will be provided with access to THC Global's medicinal cannabis for use in product development by Meluka Honey of novel cannabis blended products including incorporation of Melaleuca tea tree extract from EVE's tea tree plantations. Additionally, THC Global's current and planned operations in Australia, North America and Asia could positively assist in the production, and distribution of proposed Meluka Honey cannabis and tea tree honey products.

This manufacturing licence secured by THC Global is for its Southport Manufacturing Facility, which THC Global states as being the largest bio-pharmaceutical extraction facility in the Southern Hemisphere. Being able to access this site for EVE's tea tree and Meluka Honey cannabis projects is a significant advantage to EVE.

With THC Global having secured this second manufacturing licence for medicinal cannabis, now at its Southport facility, EVE now has an additional option, within close proximity of its plantations, for further research and development activities in partnership with THC Global.

THC Global has previously leased a portion of organic farm land from EVE for the cultivation of medicinal cannabis. The currently leased land is the subject of a medicinal cannabis cultivation licence lodged by THC Global last year, which has now progressed to "assessment phase" by the Australian Office of Drug Control (ODC) and is expected to be received this year. Once received, THC Global will be licenced to cultivate medicinal cannabis on EVE's site, with additional expansion into a larger area on the site in progress.

THC Global's Manufacture Licence receipt at Southport is an important milestone in the joint strategy between EVE and THC Global towards development of medicinal cannabis honey, as well as other potential future activities between the companies.

Tea Tree Extract R&D

EVE's R&D program for the production of a specialised ancestral melaleuca tea tree extract at THC's Southport facility has progressed to a testing phase. The advanced technology available at THC's Southport facility for botanical extractions is assisting EVE in advancing the pathway to market for its tea tree honey-based products.

Mr Ken Charteris, CEO of THC Global commented:

"We are pleased to announce a second manufacture licence, this time for our Southport Facility, the largest bio-pharmaceutical extraction facility in the Southern Hemisphere. Through our partnership with EVE, we are exploring new product development avenues and to date are pleased with our success. We look forward to working closer with EVE as we move towards commercial availability of our GMP Active Pharmaceutical Ingredient extracts from which we expect to be able to develop products including Meluka Health's cannabis honey".

Ben Rohr, Investment Director of EVE Investments commented:

"EVE has an established relationship with THC's Southport facility via its previous R&D work with the Tea Tree extract. The granting of a manufacture licence for the Southport Manufacturing Facility is another critical milestone in our R&D pathway for Meluka Health's cannabis honey products as well as other potential opportunities with our Tea Tree extract".

For further information:

Ben Rohr

Investment Director

+ 61 8 6465 5500

benr@eveinvestments.com.au

About EVE Investments

EVE Investments invests in companies with a focus on the medical nutrition sector. The Company's investment strategy has a three pronged approach.

1. To invest in businesses that are in the early growth phase with the aim to support their expansion programs.
2. To identify products that have unique medicinal properties and a global reach application.
3. Preference for natural organic products that have demonstrated medicinal benefits.

For further information, please visit www.eveinvestments.com.au and follow us on Twitter [@EVEInvestments](https://twitter.com/EVEInvestments)

About Meluka Health Pty Ltd (100% EVE)

Meluka Health Pty Ltd is a wellness and nutrition company that develops and sells its naturally derived, organic and ecologically pure products created using its old growth Australian Melaleuca tea tree plantation which are acclaimed for their medicinal activity.

THC Global Group Limited (ASX: THC)

THC Global operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and two Manufacture Licences through its domestic medicinal cannabis subsidiaries THC Pharma and Canndeo. THC Global has secured a significant cannabis growing capacity over multiple cultivation projects. and owns a licenced GMP ready high-volume bio-pharma extraction facility with attached testing and product development laboratory. THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. THC Global is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence – both in cannabis and in hydroponics equipment. THC Global's Canadian cannabis operation, Vertical Canna, holds property in Nova Scotia, Canada being developed into a large scale cannabis production site. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponics equipment and supplies for cannabis cultivation. For further information, please visit thc.global.